Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. - Wikidata - awgldk - TriplyDB

Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.

Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.

http://www.wikidata.org/entity/Q50559084

about

Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma Hepatitis C virus infection and type 1 and type 2 diabetes mellitus Cytokinome profile evaluation in patients with hepatitis C virus infection Cytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infection APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysis The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies.Significance of vitamin d receptor gene polymorphisms for risk of hepatocellular carcinoma in chronic hepatitis C.Achieving Sustained Virological Response in Hepatitis C Reduces the Long-Term Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis Employing Relative and Absolute Outcome Measures.Neutrophil-to-lymphocyte ratio as a predictor of response to peginterferon plus ribavirin therapy for chronic hepatitis C.The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy Hepatocellular Carcinoma in a non-Cirrhotic Liver of a HCV-Positive Woman with Sustained Viral Response Impact of hepatitis C virus eradication on hepatocellular carcinogenesis.Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development.Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis.Influence of insulin resistance on the development of hepatocellular carcinoma after antiviral treatment for non-cirrhotic patients with chronic hepatitis C.Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy.Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy.Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review.A Different Perspective for Management of Diabetes Mellitus: Controlling Viral Liver Diseases Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications.Steatosis and insulin resistance in response to treatment of chronic hepatitis C.Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy.Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye.Reply to antiviral therapy and hepatocellular carcinogenesis.Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: a nation-wide cohort study.Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy.High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy.Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C.SIGNIFICANT IMPROVEMENT OF GLYCAEMIC CONTROL IN DIABETIC PATIENTS WITH HCV INFECTION RESPONDING TO DIRECT-ACTING ANTIVIRAL AGENTS.Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes.Rapidly growing hepatocellular carcinoma after direct-acting antiviral treatment of chronic hepatitis C.Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C.Simple score to predict risk of hepatocellular carcinoma in chronic hepatitis C patients with advanced fibrosis after pegylated interferon and ribavirin therapy.

P2860

Q26766707-744B7F28-32D6-4655-9A28-4D0E38C7B3B5 Q26829202-F03F5AA6-3E8A-47EE-B62E-A35B19DC3B22 Q26849696-A3F51B29-A3DB-495D-A24F-C8F64FA23788 Q28480545-80C3D705-DE77-4CE6-9479-F23DC2929770 Q30250088-583BEDD1-E917-4EBA-9FA4-3BAC1BA9BD11 Q33646525-916F84A2-16C1-4438-97E8-5FB83AFE6149 Q34113485-334BD979-149F-48AF-8465-E540D83C44CF Q34369199-4E57FDCD-CB10-4250-A4D9-89E42C817FE2 Q34497272-F562C8FE-AD36-43CB-BD12-8FA3E8F1961D Q34628015-5A8D1B57-611C-4C7D-8B58-3B2FDFBA5AF9 Q35135141-F6826167-A625-4748-819F-7D36FB2CFC4C Q35560273-F5BF4423-8B09-4F9A-BE9A-F380DD61B655 Q35985401-CB06DE3D-DEDC-40AF-AB9F-0547D96650FD Q36329125-660DEF34-D9A7-4BA4-B872-081CC1201D35 Q36334385-3BDA9355-0DE3-472C-8138-C146F19DA103 Q36611684-C70650B9-ABF6-482C-946E-E149D3E5EB90 Q37158382-DA6BB2E3-AA3D-48D8-BD67-2EFF0457E35A Q37279232-5C07D9D5-1B1B-44E2-AF9E-56F7B88D45A1 Q37328172-692B7C0F-B3ED-4EA5-92F9-CBCEE63467CD Q37685491-59D3CF87-B5CD-4D77-B7FB-1CE7E2DBCF08 Q37703437-D8A84D65-FFAC-429B-8114-781F9B5D6B15 Q37879191-1D2FE868-C9F7-4E3D-9784-24C2FE19A95D Q37974700-711D56AB-8B9A-4D00-BD99-38EAD2D7980D Q38232812-1B543265-0BA5-4C43-941B-83EE6D955189 Q38522791-E10BBAB8-597B-4BA1-B94C-EFCFB911E7B7 Q38945243-3BCE9C13-431D-4F1D-ABE1-BA43D00BD683 Q39039478-36791846-43B2-4C70-8A29-452C877D05F3 Q40695544-9C718252-D129-4723-BAD5-7640D163A3B6 Q40722730-3399DE6D-E98A-429F-A331-C65645CAC762 Q40873258-D2CEEE52-6FD5-414B-906F-C2D85052642C Q41535486-A1BAE543-E571-46BB-94E6-C45B64804856 Q41928201-C766AD38-EE88-49EC-85DF-C6AC5399C036 Q42250363-162AE2B5-677B-44B8-8AA3-0E6C74455CD9 Q48106729-612290DC-C7BF-46FB-9390-A9BE06D1ADD6 Q51761924-48B7F738-B3B6-4DEE-9B8F-DF66C2DFC58D Q54944680-7724CC65-CBEB-4F69-AEA6-E5305B9517A6

P2860

Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.

http://www.wikidata.org/entity/Q50559084

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Impact of diabetes mellitus on ...... feron-based antiviral therapy.

@en

Impact of diabetes mellitus on ...... feron-based antiviral therapy.

@nl

type

label

Impact of diabetes mellitus on ...... feron-based antiviral therapy.

@en

Impact of diabetes mellitus on ...... feron-based antiviral therapy.

@nl

prefLabel

Impact of diabetes mellitus on ...... feron-based antiviral therapy.

@en

Impact of diabetes mellitus on ...... feron-based antiviral therapy.

@nl

P1433

Q50559084-04466285-CC69-4E74-8D78-AA6016E0D28A

P1476

Q50559084-475B7CEA-69BA-45D6-AD97-BDF3C96C5F16

P2093

Q50559084-003855B4-AC79-4653-8B31-CD40191C3752

Q50559084-00B53B4D-5825-4D2A-89A7-B2E4AE522134

Q50559084-85FE7535-8E55-467C-BC1D-83F8232BF604

Q50559084-9873E296-DE54-4697-B4C9-82E6362755F4

Q50559084-BE1E1F85-4D8C-4C1C-A377-D5052DE51630

Q50559084-BFA1B382-0F53-48ED-A42D-A358D4EED202

Q50559084-E7442866-9550-4D93-AA1F-F5A4594C2823

P2860

Q50559084-04719316-0FEC-4D4A-9841-4544749A8459

Q50559084-070514CF-4F53-4AA4-A617-815FC87FAB7E

Q50559084-188768B6-5DF2-4B89-9F11-174136D1561F

Q50559084-29766DA5-C3D3-472E-A20D-C843F8A14102

Q50559084-2A71AF48-FFC7-43BF-935F-BCF16A39D60F

Q50559084-3124056B-43DA-4298-99D6-E1AA9CFA1DD8

Q50559084-3839D8EB-FA32-4848-9300-8D9D0D35B932

Q50559084-4D0B94ED-BF4A-42FA-B108-9EE617F6EE54

Q50559084-4D6082AB-A90D-4A01-B973-E274BFF9DF11

Q50559084-5764C1CE-CAB9-4F7C-84EA-38F8DD9CD1DD

P304

Q50559084-A6F567BA-694D-4CA1-B741-EFDE77DA0104

P31

Q50559084-53E2B82D-668F-4855-969F-EECAFE708F70

P356

Q50559084-BC81016A-8139-4F0E-B84F-0D81FAE554F5

P433

Q50559084-EEF6CFBA-E181-4E3D-B8C1-8C4BE5EC1A02

P478

Q50559084-58969049-CDBE-41C2-A4AD-1AC198811620

P577

Q50559084-3F0FB691-212D-4392-824F-032C3DE06AAE

P5875

Q50559084-9FEAFF62-3D0B-49BA-A00A-9854F8E98CD2

P698

Q50559084-2BA0FBE6-FB93-42C2-9EAD-ADB1147E9FD6

P356

P1433

International Journal of Cancer

P1476

Impact of diabetes mellitus on ...... feron-based antiviral therapy.

@en

P2093

Chao-Hung Hung

http://www.w3.org/2001/XMLSchema#string

Chien-Hung Chen

http://www.w3.org/2001/XMLSchema#string

Chih-Yun Lin

http://www.w3.org/2001/XMLSchema#string

Chuan-Mo Lee

http://www.w3.org/2001/XMLSchema#string

Jing-Houng Wang

http://www.w3.org/2001/XMLSchema#string

Sheng-Nan Lu

http://www.w3.org/2001/XMLSchema#string

Tsung-Hui Hu

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

Management of hepatocellular carcinoma

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies.

Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study.

Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance.

P304

2344-2352

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.25585

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

128

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45407562

http://www.w3.org/2001/XMLSchema#string

P698

20669224

http://www.w3.org/2001/XMLSchema#string